CUA: Muscle-invasive Bladder Cancer (2019): Difference between revisions
Urology4all (talk | contribs) Created page with " '''See AUA Muscle-invasive Bladder Cancer Guidelines 2017''' ===== Diagnosis and Evaluation ===== * '''Clinical staging (3): TURBT pathology, exam under anesthesia, imaging''' ** '''TURBT pathology''' *** '''MIBC should be diagnosed with a good quality TURBT including muscularis propria that confirms muscle invasion''' **** '''In those rare instances where''' evidence (radiographic or clinical (e.g. bimanual examination)) supports a clear-cut clinical diagnosis of MI..." |
Urology4all (talk | contribs) No edit summary |
||
| Line 261: | Line 261: | ||
# As per the AUA MIBC guidelines, which laboratory investigations should be ordered during the follow-up of a patient treated for MIBC? | # As per the AUA MIBC guidelines, which laboratory investigations should be ordered during the follow-up of a patient treated for MIBC? | ||
#* Electrolytes, Cr, and vitamin B12 | #* Electrolytes, Cr, and vitamin B12 | ||
== References == | |||
* [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6737737/ Kulkarni, Girish S., et al. "Canadian Urological Association guideline: Muscle-invasive bladder cancer." ''Canadian Urological Association Journal'' 13.8 (2019): 230.] | |||